The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

Fatty liver disease affects more than 1 in 3 adults and often has no symptoms. A new drug developed with Tulane researchers ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB ...

Dr Rowan French insists lasting weight loss can only be achieved through a balanced approach to psychology, exercise and ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

About 1 in 5 classified as overweight based on BMI alone considered to have obesity according to European society definition.